← Back to Screener
Kyverna Therapeutics, Inc. Common Stock (KYTX)
Price$8.22
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-1.41%
Price vs S&P 500 (4W)-8.92%
VGM Score66.15
Market Capitalization$517.98M
All Metrics
Book Value / Share (Quarterly)$3.23
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.50
Price vs S&P 500 (YTD)-20.30%
EPS (TTM)$-3.28
10-Day Avg Trading Volume0.88M
EPS Excl Extra (TTM)$-3.28
EPS (Annual)$-3.34
ROI (Annual)-47.48%
Cash / Share (Quarterly)$3.91
ROA (Last FY)-41.69%
EBITD / Share (TTM)$-3.34
Cash Flow / Share (Annual)$-2.56
P/B Ratio2.65x
P/B Ratio (Quarterly)2.67x
Net Income / Employee (Annual)$-947,800
Net Interest Coverage (TTM)-13174.00x
ROA (TTM)-64.86%
EPS Incl Extra (Annual)$-3.34
Current Ratio (Annual)7.75x
Quick Ratio (Quarterly)7.97x
3-Month Avg Trading Volume0.86M
52-Week Price Return223.95%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)73.73x
Asset Turnover (Annual)0.10x
52-Week High$13.67
EPS Excl Extra (Annual)$-3.34
26-Week Price Return14.52%
Quick Ratio (Annual)7.65x
13-Week Price Return4.93%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)8.15x
Enterprise Value$510.81M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-411.29%
Cash / Share (Annual)$4.62
3-Month Return Std Dev84.24%
Net Income / Employee (TTM)$-1,167,200
ROE (Last FY)-47.64%
EPS Basic Excl Extra (Annual)$-3.34
Total Debt / Equity (Quarterly)0.13x
EPS Incl Extra (TTM)$-3.28
ROI (TTM)-76.78%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)195.75%
Year-to-Date Return-9.36%
5-Day Price Return-1.73%
EPS Normalized (Annual)$-3.34
Net Profit Margin (Annual)-411.29%
Month-to-Date Return-3.18%
EBITD / Share (Annual)$-3.71
Operating Margin (Annual)-418.28%
LT Debt / Equity (Annual)0.11x
LT Debt / Equity (Quarterly)0.13x
EPS Basic Excl Extra (TTM)$-3.28
P/B Ratio (Annual)2.31x
Book Value / Share (Annual)$3.85
Price vs S&P 500 (13W)-4.82%
Beta1.59x
Revenue / Share (TTM)$0.00
ROE (TTM)-81.87%
52-Week Low$2.47
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.66est. -0.77
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KYTXKyverna Therapeutics, Inc. Common Stock | — | — | B | $8.22 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases. Its pipeline includes KYV-101, an autologous CD19 CAR T-cell therapy, and KYV-201, an allogeneic version designed for multiple autoimmune indications.